AbbVie Inc. (ABBV)
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
3 Dividend Aristocrats to Buy in July
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026.
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
3 Dividend Stocks to Buy Hand Over Fist in July
Dividend investors entering July 2026 have a rare setup: Three of the market's most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year.
AbbVie: Apogee Deal Just Widened An Already Dominant Moat
AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, with combined sales surpassing Humira's peak and continuing to grow at 20–30% post-LOE. Zumilokibart, Apogee's lead asset, offers best-in-class efficacy and dosing convenience in atopic dermatitis, with Phase 3 data expected in 2028 and approval in 2030.
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
